三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABU 三倍做多标普生物-Direxion

休市中 05-01 16:00:00 EDT

173.61

-3.95

-2.22%

盘后173.60

-0.01-0.01%

19:52 EDT

最高177.74	最低167.94	成交量55.67万
今开175.60	昨收177.56	日振幅5.52%
总市值5.16亿	流通市值5.16亿	总股本297.45万
成交额9,649万	换手率18.72%	流通股本297.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":173.61,"timestamp":1777665600000,"preClose":177.56,"halted":0,"volume":556676,"hourTrading":{"tag":"盘后","latestPrice":173.6,"preClose":173.61,"latestTime":"19:52 EDT","volume":4514,"amount":781579.6498,"timestamp":1777679523562,"change":-0.01,"changeRate":-0.000058,"amplitude":0.008122},"delay":0,"changeRate":-0.022246001351655713,"floatShares":2974486,"shares":2974486,"eps":0,"marketStatus":"休市中","change":-3.95,"latestTime":"05-01 16:00:00 EDT","open":175.6,"high":177.74,"low":167.9401,"amount":96489152.0884,"amplitude":0.055192,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":177.56,"sharesOutstanding":3024486,"nav":177.43,"aum":527762870.66,"dividendRate":0.00714,"bidAskSpread":0.00199,"preHourTrading":{"tag":"盘前","latestPrice":175.704,"preClose":177.56,"latestTime":"09:29 EDT","volume":999,"amount":176410.69272,"timestamp":1777642199178,"change":-1.856,"changeRate":-0.010453,"amplitude":0.02585},"postHourTrading":{"tag":"盘后","latestPrice":173.6,"preClose":173.61,"latestTime":"19:52 EDT","volume":4514,"amount":781579.6498,"timestamp":1777679523562,"change":-0.01,"changeRate":-0.000058,"amplitude":0.008122},"volumeRatio":1.0435793599735206,"impliedVol":0.841,"impliedVolPercentile":0.3267},"requestUrl":"/m/hq/s/LABU","defaultTab":"news","newsList":[{"id":"2632504618","title":"阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2632504618","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632504618?lang=zh_cn&edition=full","pubTime":"2026-05-01 16:14","pubTimestamp":1777623240,"startTime":"0","endTime":"0","summary":"在乳腺癌候选药物未能在一项关键的咨询委员会投票中获得支持后，英国制药集团阿斯利康表示，该公司将继续与美国监管机构合作，对该药物进行审查。该公司周四晚间表示，美国食品药品管理局的肿瘤药物咨询委员会以6比3的投票结果，对乳腺癌治疗候选药物camizestrant的获益-风险评估给出否定性意见。阿斯利康的股价在周五开盘交易中下跌了约1.8%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-01/doc-inhwktza5459710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU0058720904.USD","BK4588","LU2237443549.SGD","BK4585","LU2236285917.USD","AZN","BK4568","LU0109394709.USD","LU2237443978.SGD","LABU","LU2237443382.USD","LU2417539215.USD","LU0320765992.SGD","LU2237443895.HKD","LU0889565916.HKD","LU1829250122.USD","LU2237443465.HKD","LU0289739699.SGD","LU2456880835.USD","LU2462157665.USD","LU2237443622.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632668411","title":"FDA批准Axsome新药用于治疗阿尔茨海默病激越症状","url":"https://stock-news.laohu8.com/highlight/detail?id=2632668411","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632668411?lang=zh_cn&edition=full","pubTime":"2026-05-01 03:12","pubTimestamp":1777576320,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局周四正式批准Axsome Therapeutics公司的AXS-05用于治疗阿尔茨海默病相关的激越症状。FDA此前已授予该申请优先审评资格，目标行动日期正是今日。此次获批将帮助Axsome拓展中枢神经系统药物版图。多达76%的阿尔茨海默病患者会出现激越症状，表现为情绪困扰、言语和身体攻击、易怒和行为失控。　　随着此次获批，AXS-05将为数百万阿尔茨海默病患者及其家庭提供新的治疗选择。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-01/doc-inhwinfv0998286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590146","title":"美国FDA拟将减肥药从复方制剂清单中剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590146","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631590146?lang=zh_cn&edition=full","pubTime":"2026-04-30 23:11","pubTimestamp":1777561860,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局宣布，拟将司美格鲁肽和替尔泊肽等GLP-1类减肥药物从允许复方制剂生产的清单中剔除，理由是这些药物已不再处于短缺状态。FDA于2025年2月将司美格鲁肽从短缺清单中移除，替尔泊肽随后也被移出。　　FDA在4月1日发布的最新政策说明中明确指出，任何被认定为“基本上是商业可得药品复制品”的复方制剂将不再享有豁免权。目前，FDA正加大执法力度，已向70多家涉嫌虚假宣传的远程医疗公司发出警告信。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-30/doc-inhwhzrz1185619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188109821","title":"医疗保健板块动态：市场焦点对话","url":"https://stock-news.laohu8.com/highlight/detail?id=1188109821","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188109821?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:23","pubTimestamp":1777537402,"startTime":"0","endTime":"0","summary":"1039 GMT - 葛兰素史克首席执行官卢克·米尔斯表示，这家英国制药巨头未来的交易或将延续其近期斥资22亿美元收购过敏药物开发商RAPT Therapeutics的模式。米尔斯补充道，由于拓展新领域的壁垒较高，葛兰素史克在未来的并购中更倾向于聚焦已有商业布局的领域或相邻赛道。该集团于今年1月米尔斯接任CEO数周后敲定对RAPT的收购，并于3月完成交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XLV","BK4581","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560116","title":"艾伯维(ABBV.US)乌帕替尼斑秃适应症已向美国FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560116","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631560116?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:40","pubTimestamp":1777452029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月28日，艾伯维宣布，已向美国FDA递交乌帕替尼的新适应症上市申请，用于治疗成人和12岁及以上青少年重度斑秃。乌帕替尼是艾伯维研发的一款口服、高选择性JAK1抑制剂，目前正在多种免疫介导性疾病中对其进行研究。乌帕替尼于2019年首次在美国获批上市，2022年2月获批进入中国。艾伯维表示，乌帕替尼正在针对斑秃、化脓性汗腺炎、大动脉炎、系统性红斑狼疮及白癜风开展III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ABBV","IE000BZT7R73.USD","LU0949170772.SGD","LU2023251221.USD","LU2237443465.HKD","LU0310800379.SGD","IE00B42XCP33.USD","IE000MB6IJN5.SGD","LABU","IE00BSNM7G36.USD","LU0289961442.SGD","LU1244550577.SGD","LU0689472784.USD","LU0029864427.USD","LU2089284900.SGD","SG9999001440.SGD","LU0211327993.USD","SG9999003800.SGD","LU0432979614.USD","LU1496350502.SGD","LU0820561909.HKD","LU0069063385.USD","LU2468319806.SGD","LU1244550221.USD","LU0511384066.AUD","LU1291159041.SGD","LU2112291526.USD","LU1267930490.SGD","LU1003077747.HKD","IE0004445239.USD","BK4139","LU0256863811.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE000SO60NU8.SGD","LU1074936037.SGD","LU2357627491.SGD","LU0823416689.USD","LU0256863902.USD","SG9999015952.SGD","LU0211328371.USD","LU0795875169.SGD","LU0289739699.SGD","BK4581","LU2129689431.USD","LU0965509101.SGD","IPOS","LU1267930573.SGD","LU0128525929.USD","IE00BVYPNW00.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631538837","title":"FDA启动试点计划实时监测临床试验数据，旨在加速审批流程","url":"https://stock-news.laohu8.com/highlight/detail?id=2631538837","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631538837?lang=zh_cn&edition=full","pubTime":"2026-04-29 03:24","pubTimestamp":1777404240,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日宣布推出一项全新的试点项目，旨在通过实时监测临床试验数据来加速药品审批流程。此举是FDA局长马蒂·马卡里推动监管改革、提升审评效率的核心举措之一。FDA局长曾在摩根大通医疗健康大会上表示，在当前科技水平下，一款新药从研发到上市仍需10到12年“在伦理上是不可接受的”。在坚持科学审评底线的前提下，FDA正通过简化审批流程、推动AI技术应用、削减部分动物实验要求等方式，整体提高监管运行效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-29/doc-inhwaxzn8203584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630372568","title":"联邦制药(03933)：TUL321胶囊获美国FDA新药临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2630372568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630372568?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:55","pubTimestamp":1777370158,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，本公司全资附属公司珠海联邦制药股份有限公司研发的1类创新药TUL321 胶囊的新药临床试验注册申请获美国食品药品监督管理局批准，IND编号为180385。TUL321 胶囊是新一代补体B因子抑制剂。CFB为补体系统旁路途径核心限速丝氨酸蛋白酶原，病理状态下异常激活导致旁路通路失控，介导组织损伤，从而引发多种疾病。本次获批是本公司于自身免疫疾病治疗领域创新研发取得的又一重要进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1191","LABU","03933","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143202254","title":"医疗保健行业动态聚焦：市场热点解析","url":"https://stock-news.laohu8.com/highlight/detail?id=1143202254","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143202254?lang=zh_cn&edition=full","pubTime":"2026-04-28 00:23","pubTimestamp":1777306981,"startTime":"0","endTime":"0","summary":"两家公司在抗癌药物Enhertu和Datroway方面是合作伙伴。第一三共上周以审查其肿瘤产品组合和研发管线的供应计划为由，推迟了2026财年业绩的发布。分析师认为，此举可能与第一三共解决其生产网络问题的努力有关。他们补充道，预计这对Enhertu和Datroway等抗癌药物的销售影响甚微或没有影响，因此对阿斯利康不会产生实质性影响。阿斯利康股价上涨0.3%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","UBS","BK4588","XBI","XLV","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158727907","title":"医疗保健行业动态聚焦：市场观点速递","url":"https://stock-news.laohu8.com/highlight/detail?id=1158727907","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158727907?lang=zh_cn&edition=full","pubTime":"2026-04-25 00:22","pubTimestamp":1777047769,"startTime":"0","endTime":"0","summary":"生物梅里埃稳健的资产负债表与净现金头寸为这家制药企业提供了并购机遇。在检测领域，该法国药企仍被列为首选标的，其竞争对手凯杰与索灵或因呼吸道疾病季温和及中东冲突影响而承压。股价当前下跌2.7%至71.30欧元，年内累计跌幅达35%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XLV","BK4581","XBI","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629890197","title":"前高盛合伙人李逸斌出任摩根大通(JPM.US)全球医疗保健投行业务联席主管","url":"https://stock-news.laohu8.com/highlight/detail?id=2629890197","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629890197?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:45","pubTimestamp":1777013116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体报道，摩根大通 任命Jerry Lee李逸斌、Nick Richitt为全球医疗保健投资银行联席主管。Jerry Lee，刚于今年第一季度加入摩根大通，此前他在高盛工作逾19年，他于2020年便晋升为高盛合伙人，离开高盛前担任全球生物医药投行业务和医疗保健投行业务主管，职业生涯中已为逾3000亿美元的已宣布并购交易提供过咨询。Jerry Lee，1999年获耶鲁大学学士学位、2007年获宾夕法尼亚大学沃顿商学院MBA学位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640476718.USD","LU1868836757.USD","LU0345769631.USD","LU0310799852.SGD","LU1720051017.SGD","VHT","GSX","LU0061475181.USD","LU1917777945.USD","LU2430703178.SGD","LU0859254822.USD","IE00BN8TJ469.HKD","LABU","LU0215105999.USD","XBI","LU2750360997.AUD","LU2054465674.USD","LU1267930490.SGD","LU0203347892.USD","LU1868836914.USD","JPO","LU2237443622.USD","BK4207","LU1551013425.SGD","LU1064131342.USD","LU1366192091.USD","LU2237443549.SGD","LU2756315318.SGD","IE00BDRTCR15.USD","LU1548497426.USD","LU2237438978.USD","XLV","LU0265550359.USD","LU0203345920.USD","IE00BDCRKT87.USD","BK4127","LU0345770993.USD","LU2552382132.HKD","LU2746668461.USD","BK4533","LU2023250504.SGD","LU1145028129.USD","LU0256863811.USD","LU1363072403.SGD","IE0034235295.USD","LU2592432038.USD","LU0976567544.SGD","BK4534","JPMO","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852068","title":"美国FDA批准再生元基因疗法，用于治疗遗传性耳聋","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852068","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852068?lang=zh_cn&edition=full","pubTime":"2026-04-24 03:01","pubTimestamp":1776970906,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日批准了再生元制药公司开发的基因疗法DB-OTO，用于治疗由OTOF基因突变导致的先天性深度听力损失。这是全球首款获批用于治疗遗传性耳聋的药物疗法，标志着耳科治疗领域进入全新纪元。　　再生元表示，计划进一步推进该疗法在更广泛患者群体中的应用，同时公司还在开发针对其他遗传性耳聋相关靶点的基因疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5070006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629852486","title":"美国FDA拒绝批准Grace Therapeutics脑卒中药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629852486","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629852486?lang=zh_cn&edition=full","pubTime":"2026-04-24 02:43","pubTimestamp":1776969780,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局近日已向Grace Therapeutics发出完整回应函，拒绝批准其候选药物治疗特定类型脑卒中（中风）的上市申请。FDA在函件中指出，根据现有数据，暂无法确认该药物的临床获益大于风险，并要求公司在药品获批前补充相关的临床试验数据或生产质量控制信息。　　Grace Therapeutics方面随即回应称，正对FDA的反馈进行详细评估。　　此次拒绝为该公司的新药上市之路增加了新的不确定性，至于Grace是选择提起上诉还是重新提交申请，还有待公司进一步披露。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-24/doc-inhvpqks5066320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","LENZ","BK4588","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158690158","title":"医疗保健板块动态聚焦：罗氏业绩符合预期，科利耳前景承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1158690158","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158690158?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:24","pubTimestamp":1776932649,"startTime":"0","endTime":"0","summary":"0810 GMT - 杰富瑞分析师指出，罗氏第一季度销售额基本符合市场预期。这家瑞士制药巨头将于周四晚些时间举行电话会议，预计将重点讨论其长期销售前景。分析师补充称，市场将密切关注罗氏对多发性硬化症药物芬努替尼的信心表现，同时其乳腺癌药物Giredestrant的商业化机遇也引发投资者兴趣。罗氏股价当前上涨2.3%至320.4瑞士法郎。流行病防范创新联盟已承诺提供最高5430万美元支持疫苗研发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","XLV","BK4585","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076948","title":"探索健康保险发展新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076948","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629076948?lang=zh_cn&edition=full","pubTime":"2026-04-23 06:00","pubTimestamp":1776895205,"startTime":"0","endTime":"0","summary":"近日，第一届海南自贸港博鳌乐城健康保险高质量发展大会举行。来自监管部门、保险行业、高校和医疗机构的代表齐聚一堂，围绕加快发展健康保险，推动健康保险与医疗健康产业深度融合创新等话题展开讨论，共同探讨健康保险高质量发展新路径。健康保险主要包括商业医疗保险、商业长期护理保险、失能收入损失保险和疾病保险四大类险种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233714848012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4581","LABU","BK4585","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629209736","title":"美股医疗 REITs 融资遇冷：National Healthcare(NHP.US)折价完成 IPO，最终募资4.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629209736","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629209736?lang=zh_cn&edition=full","pubTime":"2026-04-22 14:35","pubTimestamp":1776839700,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，房地产投资信托基金National Healthcare Properties Inc.的 IPO 定价低于其原定区间，最终筹集了4.62亿美元。声明显示，National Healthcare计划将募集资金用于多种用途，包括偿还其循环信贷额度中约1.86亿美元的借款，以及为未来的物业收购提供资金。根据招股文件，National Healthcare在2025年营收为3.423亿美元，净亏损为5770万美元；而上年同期营收为3.54亿美元，净亏损为1.903亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NHP","BK4581","159891","BK4585","XLV","BK4588","IPOS","CFA","XBI","LABU","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629930310","title":"葛兰旗下中欧医疗健康混合一季报：药明康德(603259.SH)位列第一大重仓股 二季度看好创新产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2629930310","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629930310?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:52","pubTimestamp":1776826345,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月22日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第1季度报告。葛兰表示，一季度基于长期价值投资思路，继续重点关注创新药械及其产业链、消费医疗等领域。调仓换股方面，与2025年第4季度相比，中欧医疗健康混合在一季度减仓了康龙化成、泰格医药等个股，增持了凯莱英、信立泰、海思科、科伦药业，而艾力斯新进持仓前十。创新药及产业链预计将延续高景气度，是二季度重点关注方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1808992512.USD","LU2242644610.SGD","LU0456842615.SGD","LU0348766576.USD","BK4581","BK4550","LU2125910500.SGD","LABU","LU0708995583.HKD","LU1934453819.USD","BK1141","BK1576","LU2488822045.USD","LU2045819591.USD","LU1997244956.HKD","LU1969619763.USD","BK4585","BK0216","LU1997245177.USD","LU0320764599.SGD","LU1979443071.USD","LU2328871848.SGD","159760","XBI","BK1583","LU0348767384.USD","603259","LU0052750758.USD","02359","LU2495084118.USD","LU1997245094.SGD","VHT","XLV","BK4588","IXJ","LU1046422090.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629080017","title":"美国健康保险公司股价盘前上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2629080017","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629080017?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:29","pubTimestamp":1776767357,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月21日，美国健康保险公司股价盘前上涨，此前联合健康第一季度利润超出预期。CVS健康上涨3.3%，Elevance上涨3.2%，Cigna上涨1.3%，Humana上涨2.9%，MolinaHealthcare上涨3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712493616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"059177759f9d48b3b3bd76393f707d29","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712493616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XBI","BK4581","XLV","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628622524","title":"顶级阵容齐聚！乐城这场大会共探健康保险未来新生态，最新议程→","url":"https://stock-news.laohu8.com/highlight/detail?id=2628622524","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628622524?lang=zh_cn&edition=full","pubTime":"2026-04-17 09:41","pubTimestamp":1776390060,"startTime":"0","endTime":"0","summary":"　　4月16日-18日，第一届海南自贸港博鳌乐城健康保险高质量发展大会暨第三届多层次健康保障研讨会将在博鳌亚洲论坛东屿岛大酒店举办。推动商业健康保险向质量效益、创新驱动转型，已成为完善中国特色多层次医疗保障体系、服务民生福祉的时代任务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2026-04-17/doc-inhuuimk6607344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XLV","BK4585","LABU","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628240719","title":"中信证券：药价形成机制迎来大调整 医疗健康产业政策改革进入密集期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628240719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628240719?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:12","pubTimestamp":1776384738,"startTime":"0","endTime":"0","summary":"医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。中信证券主要观点如下：事件：4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，15日国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","LU1328615791.USD","LU2148510915.USD","LU1997245177.USD","BK0012","LU1255011170.USD","BK0183","XBI","LU1997244956.HKD","BK0196","XLV","LU0405327148.USD","LU1064130708.USD","LU1580142542.USD","LABU","LU0405327494.USD","BK0276","VHT","LU2289578879.USD","BK4585","IXJ","BK0028","BK0188","BK1521","LU2495084118.USD","LU1655091616.SGD","LU1781817850.SGD","LU1794554557.SGD","BK1564","BK4581","06030","LU1720050803.USD","LU1997245094.SGD","159760","BK4550","LU1064131003.USD","600030","BK4588","BK1516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627214491","title":"美股异动｜Hims & Hers涨超7%，美国FDA将审议放宽多肽产品限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2627214491","media":"格隆汇","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627214491?lang=zh_cn&edition=full","pubTime":"2026-04-16 22:52","pubTimestamp":1776351127,"startTime":"0","endTime":"0","summary":"美国互联网医疗公司Hims & Hers Health(HIMS.US)涨超7%，报26.02美元。消息面上，美国食品及药物管理局(FDA)将于7月举行为期两日的咨询委员会会议，讨论是否允许持牌配制药房重新制造部分于2023年被禁的多肽产品。是次审议涵盖7种多肽，相关产品被宣称可用于伤口愈合、减重及改善失眠等用途，但人体安全数据仍有限。(格隆汇)\n\n美股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：山上","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/04/16225256779394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0681},{"period":"1month","weight":0.0235},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.3248},{"period":"1year","weight":1.9227},{"period":"ytd","weight":0.0892}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.020883},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.009536},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.135885},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.001739},{"month":5,"riseRate":0.454545,"avgChangeRate":0.002711},{"month":6,"riseRate":0.727273,"avgChangeRate":0.127955},{"month":7,"riseRate":0.636364,"avgChangeRate":0.054287},{"month":8,"riseRate":0.636364,"avgChangeRate":-0.004065},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.0652},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.047038},{"month":11,"riseRate":0.818182,"avgChangeRate":0.199161},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.032237}],"exchange":"ARCA","name":"三倍做多标普生物-Direxion","nameEN":"Direxion Daily S&P Biotech Bull 3x Shares"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三倍做多标普生物-Direxion,LABU,三倍做多标普生物-Direxion股票,三倍做多标普生物-Direxion股票老虎,三倍做多标普生物-Direxion股票老虎国际,三倍做多标普生物-Direxion行情,三倍做多标普生物-Direxion股票行情,三倍做多标普生物-Direxion股价,三倍做多标普生物-Direxion股市,三倍做多标普生物-Direxion股票价格,三倍做多标普生物-Direxion股票交易,三倍做多标普生物-Direxion股票购买,三倍做多标普生物-Direxion股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三倍做多标普生物-Direxion(LABU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三倍做多标普生物-Direxion(LABU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}